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Abstract
Background: Accurate prediction of the prognosis of RCC using a single biomarker is challenging due to the
genetic heterogeneity of the disease. However, it is essential to develop an accurate system to allow better patient
selection for optimal treatment strategies. ARL4C, ECT2, SOD2, and STEAP3 are novel molecular biomarkers
identified in earlier studies as survival-related genes by comprehensive analyses of 43 primary RCC tissues and RCC
cell lines.
Methods: To develop a prognostic model based on these multiple biomarkers, the expression of four biomarkers
ARL4C, ECT2, SOD2, and STEAP3 in primary RCC tissue were semi-quantitatively investigated by
immunohistochemical analysis in an independent cohort of 97 patients who underwent nephrectomy, and the
clinical significance of these biomarkers were analyzed by survival analysis using Kaplan-Meier curves. The
prognostic model was constructed by calculation of the contribution score to prognosis of each biomarker on Cox
regression analysis, and its prognostic performance was validated.
Results: Patients whose tumors had high expression of the individual biomarkers had shorter cancer-specific
survival (CSS) from the time of primary nephrectomy. The prognostic model based on four biomarkers segregated
the patients into a high- and low-risk scored group according to defined cut-off value. This approach was more
robust in predicting CSS compared to each single biomarker alone in the total of 97 patients with RCC. Especially in
the 36 metastatic RCC patients, our prognostic model could more accurately predict early events within 2 years of
diagnosis of metastasis. In addition, high risk-scored patients with particular strong SOD2 expression had a much
worse prognosis in 25 patients with metastatic RCC who were treated with molecular targeting agents.
Conclusions: Our findings indicate that a prognostic model based on four novel biomarkers provides valuable data
for prediction of clinical prognosis and useful information for considering the follow-up conditions and therapeutic
strategies for patients with primary and metastatic RCC.
Keywords: Renal cell carcinoma (RCC), Global transcriptome analysis, Prognostic model, Multiple biomarkers, ADP-
ribosylation factor-like 4C (ARL4C), Epithelial cell transforming 2 (ECT2), Superoxide dismutase 2 (SOD2), STEAP3
metalloreductase (STEAP3)
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Background
Renal cell carcinoma (RCC) represents 2–3% of all ma-
lignancies. It is the third most common malignant tumor
among genitourinary tract cancers and its incidence is
increasing [1]. Localized disease is commonly diagnosed
as an incidental finding and can be successfully managed
with nephrectomy, whereas metastatic RCC is refractory
to conventional chemotherapy. Over the last decade, the
availability of molecular targeted therapies which inhibit
vascular endothelial cell growth factor receptor (VEGFR)
and mammalian target of rapamycin (mTOR) kinase has
led to a substantial improvement in outcome for patients
with metastatic RCC [2]. However, curative treatment is
still not available and the disease finally progresses, lead-
ing to the death of the patient. The clinical outcome for
individual patients with metastatic RCC varies widely
and predicting survival is challenging because of its gen-
etic heterogeneity. Numerous molecular biomarkers in-
cluding gene expression profiling and deep- and whole-
genome sequencing have been investigated, but few sin-
gle biomarkers offer predictability across datasets and
clinical cohorts [3]. Hence, biomarkers and models that
can predict prognosis and thus aid drug development for
RCC are urgently needed. In some cancers, models
based on the expression of multiple genes have been de-
veloped to predict survival and validated across datasets
and study populations [4–7].
In previous work, we have demonstrated that RCC can
be divided into two types in response to nutritional
deprivation conditions, namely, starvation-resistant and
-sensitive cells [8]. The former had higher activity of
mitochondrial oxidative phosphorylation and glycolysis
than the latter, and included a low level of mitochondrial
reactive oxidative species due to sustained superoxide
dismutase 2 (SOD2) contributing to survival under con-
ditions of nutritional deprivation. This in turn contrib-
uted to the dormant character of RCC development.
Higher SOD2 expression in primary RCC tissues was as-
sociated with significantly shorter survival in patients
with metastatic RCC [9, 10]. To identify novel prognos-
tic biomarkers of poor prognosis, we performed global
transcriptome analysis on 43 primary RCC tissues by
next generation sequencing and detected 29 coding
genes which were highly expressed specifically in the
worst prognosis groups. Seven survival-related genes
(ARL4C, BIRC5, BUB1, CPS1, ECT2, FSTL1, and STEA
P3), whose higher levels of mRNA expression were cor-
related with poorer prognosis, were extracted by receiver
operating characteristic curve analysis with an accuracy
of > 90% for predicting the prognosis of these 43 pa-
tients [11].
In the present study, we have collected the tissue-
based biomarkers related to RCC patients, to validate
whether these biomarkers can offer us the novelty for
the therapeutic prognosis and for selection guidance of
molecular targeting drugs. In addition, to promote clin-
ical utility, the expression profile of individual bio-
markers should be immunohistochemically evaluated
using formalin-fixed paraffin-embedded tissue sections
in an independent cohort of 97 RCC patients. In these
respects, the present analysis has excluded BIRC5 and
BUB1, which had been well-established prognostic func-
tion for RCC patients [12, 13]. In addition, CPS1 and
FSTL1 could be hardly evaluated by IHC, for the tumor-
specific expression. Therefore, the following biomarkers
have been included in the present study: ADP-
ribosylation factor-like 4C (ARL4C), epithelial cell trans-
forming 2 (ECT2) and STEAP3 metalloreductase (STEA
P3), and SOD2. The prognostic impacts were investi-
gated using Kaplan-Meier curves, and the risk score of
each biomarker for prognosis was calculated through
Cox regression analysis. We developed an immunohisto-
chemical staining-based prognostic model by integrating
the expression patterns of individual biomarkers and
their risk score. We aimed to validate whether our prog-
nostic model can predict the prognosis more accurately
than each biomarker separately and be available to guide
targeted drug selection. The goal of this study is to select
patients in need of particular treatments and to deter-
mine the optimal treatment strategy.
Materials and methods
Patients
Previously, higher levels of ARL4C, ECT2, SOD2, and
STEAP3 mRNA in primary RCC tissues were reported
to be associated with worse prognosis for patients with
metastatic RCC [9, 11]. In the present study, we per-
formed expression analysis by IHC for these four gene
products and developed a risk model based on the ex-
pression profiles.
Ninety-seven patients who underwent radical or partial
nephrectomy for the treatment of RCCs at the Shiga
University of Medical Science Hospital from January
1999 to March 2016 were enrolled, and followed up to
death or to October 2016. For this study, clinical and
pathological data were obtained from medical records
with written informed consent from individual patients
and approval by the Ethics Committee of the institute
(No. R2019-165). The median age of the 97 patients was
62 years (34–82 years). The histological subtypes of RCC
were as follows: clear cell (n = 76, 78.4%), papillary (n =
12, 12.4%), chromophobe carcinomas (n = 8, 8.2%), and
unclassified (n = 1, 1.0%). T stage was pT1 in 68 (70.1%),
pT2 in 4 (4.1%), pT3 in 19 (19.6%), and pT4 in 6 (6.2%)
patients. Vascular invasion and higher grading (G3) were
identified in 67 (70.1%) and 18 (10.3%) patients, respect-
ively. Histological diagnosis and pathological grading
were according to the WHO Histological Classification
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system [14], while the clinical stage was according to the
UICC TNM classification [15]. Surgery was performed
in 70 (72.2%) patients as a curative measure, whereas the
remaining 27 (27.8%) patients underwent cytoreductive
nephrectomy because of the presence of distant metasta-
sis at the time of RCC diagnosis.
During the follow-up period, 9 patients developed dis-
tant metastasis, and therefore total 36 cases were catego-
rized as metastatic RCC patients. Finally, 16 fatalities
were observed, and all of them were due to progression
of RCC. The median follow-up period was 35 months
(1–232 months) in this cohort.
Among 36 metastatic RCC patients, only 25 cases
could be applied to the treatments of molecular target-
ing agents, due to the drug-approval status of the gov-
ernmental administration in Japan. The 25 cases were
treated with sorafenib (n = 4), sunitinib (n = 17), axitinib
(n = 14), everolimus (n = 8), and pazopanib (n = 6).
Maximum treatment responses were partial response (n
= 10), stable disease (n = 13), progressive disease (n = 1),
and not available (n = 1).
Immunohistochemistry
Surgical specimens were transferred to 10% buffered for-
malin and fixed overnight. Fixed samples were embed-
ded in paraffin and serially sliced into 5 μm sections.
After dewaxing, sections were autoclaved at 120 °C for 1
min in 10 mM sodium citrate buffer (pH 6.0) and
immersed in 0.3% H2O2. They were then incubated
overnight at 4 °C with primary antibodies against ARL4C
(diluted 1:400, #10202-1-AP, Proteintech, IL), ECT2 (di-
luted 1:200, #CF807408, Origene, MD), SOD2 (diluted 1:
1000, #06-984, Millipore Corporation, Billerica, MA)
and STEAP3 (diluted 1:400, #HPA050510, Atlas Anti-
bodies, Stockholm, Sweden). Sections were rinsed with
phosphate-buffered saline and incubated with secondary
antibody conjugated with horseradish peroxidase (Sim-
ple Stain MAX-PO, Nichirei, Tokyo, Japan) at room
temperature for 1 h. Sections were then stained with
3.3′-diaminobenzidine tetrahydrochloride and counter-
stained with hematoxylin.
Microscopic evaluation
The expression of each molecular marker was deter-
mined by IHC by comparing relative strength of expres-
sion with the adjacent normal proximal tubules as an
internal control on the same slide. We defined two
qualitative grades for specimens according to the inten-
sity of staining as (i) “high-expression” with a tumor
staining intensity equal or stronger than that of normal
proximal tubules; and ii) “low-expression” as lower in-
tensity than that of the proximal tubules, or completely
absent staining. These semi-quantitative IHC compari-
sons offer a non-ambiguous evaluation for tumor
expression of these molecules. Grading of biomarker ex-
pression with IHC was performed by two independent
researchers (R.K., T.C.), who had no information on the
clinical parameters.
Risk stratification based on multiple biomarker expression
for cancer-specific survivals in renal cell carcinoma
In addition, referring to the hazard values of univariate
Cox proportional hazards model analysis, scoring assign-
ments for developing a prognostic model with multiple
biomarkers were performed by weighting the contribu-
tion score to prognosis for each biomarker as follows:
ARL4C, 11 points; ECT2, 3 points; SOD2, 4 points, and
STEAP3 10 points (Table 1). According to these
weighted scores, we calculated the risk score for each
patient and distributed the patients into two different
groups, and searched for a meaningful significant cut-off
point for the prediction of prognosis.
Statistical analysis
The primary endpoint of this study was cancer-specific
survival (CSS). CSS was defined as the period from the
point of diagnosis to the point of death as the result of
RCC. Analyzed clinicopathological factors included age,
gender, histological type, T classification, vascular in-
volvement, pathological grade, metastasis at diagnosis,
and qualitative grade for the immunohistochemical find-
ings. CSS was estimated using the Kaplan-Meier method
and compared by log-rank and chi-square tests. The uni-
variate and multivariate Cox proportional hazards re-
gression models were used to evaluate independent
prognostic effects of the selected variables with a 95%
confidence interval. CSS intervals were used as the indi-
cator for the hazard ratio (HR). A risk model for CSS
was developed by calculating the risk score using the
value of relative risk from the univariate Cox propor-
tional hazard model. All statistical analyses were per-
formed using SPSS 22.0 (IBM Inc., Chicago, IL). All tests
Table 1 Prognostic genes for cancer-specific survival in 97 renal
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for statistical significance were two-sided. A p value <
0.05 was considered statistically significant.
Results
Prognostic ability of ARL4C and the other biomarkers for
cancer-specific survivals in renal cell carcinoma
Representative cases of high and low expression of each
molecular biomarker in pathological specimens are
shown in Fig. 1. Expression levels were categorized as
high for ARL4C in 26 cases (26.8%), for ECT2 in 28
(28.9%), SOD2 in 26 (26.8%), and STEAP3 in 10 (10.3%).
Survival curves were constructed to evaluate the associ-
ation of each biomarker with the prognosis of RCC.
Shorter CSS was seen in cases with stronger expression
of ARL4C, ECT2, SOD2, and STEAP3. The 5-year CSS
of high and low ARL4C groups was respectively 51.2%
and 95.1% with a high chi-square value (log-rank test
p < 0.001, Chi-square value = 28.11; Fig. 2a). The 5-
year CSS was 67.7% and 84.4% for the high and low
ECT2 groups, respectively (log-rank test p =0.023,
chi-square value = 5.18; Fig. 2b), 55.8% and 85.0% for
the SOD2 groups (log-rank test p = 0.005, chi-square
value = 8.02; Fig. 2c), and 46.9% and 82.6% for STEA
P3 (log-rank test p < 0.001, chi-square value = 24.35;
Fig. 2d).
Risk stratification predicts longer survival and likely
deceased cases in the whole cohort of renal cell
carcinoma patients
Using univariate Cox proportional hazards analysis, T3/
4, histological grade 3, necessity of radical nephrectomy,
presence of metastasis at diagnosis, and high expression
of all four biomarkers were found to be factors predict-
ing worse prognosis. Multivariate Cox proportional haz-
ards models indicated that the presence of metastasis at
diagnosis (HR = 9.17, 95% CI = 1.45-57.83, p = 0.018),
Fig. 1 Representative immunohistochemical images in samples from primary tumor tissues of patients with renal cell carcinoma. Expression level
of each biomarker is defined as follows; “high-expression” represents staining intensity in tumor cells equal to or higher than that of normal
proximal renal tubules; “low-expression” is define as either a negative reaction or lower positive staining than that of proximal tubules. Scale bars
indicate 50 μm
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Fig. 2 (See legend on next page.)
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T3/4 (HR = 12.00, 95% CI = 1.50–96.30, p = 0.019) and
high ARL4C expression (HR = 10.98, 95% CI = 1.77–
68.02, p = 0.010) were significant risk factors for worse
CSS (Table 2).
According to the scores contributing to the prediction
of prognosis of RCC patients, which were based on hazard
risk values of the 4 individual biomarkers in univariate
Cox regression analysis, we stratified the patients into two
different groups with meaningful cut-off points. By setting
the cut-off score to 4 points, meaning only positivity for
each SOD2, ECT2 or nothing, 97 patients were divided
into high- (> 4) or low- (≤ 4) scored groups. The latter
group of 68 cases experienced better survival, without any
deaths 8 years after the primary therapeutic procedure of
nephrectomy. This remained stably at 69.1% even after
more than 10 years (log-rank test p < 0.001, chi-square
value = 22.34, Fig. 2e). When the cut-off score was set at >
11 points, meaning positivity for ARL4C and additionally
another biomarker, none of the 22 patients in this high-
risk scored group were alive 5 years after primary neph-
rectomy (log rank test p < 0.001, chi-square value = 34.24,
Fig.2f). In comparison to ARL4C as the most prognostic
potent single biomarker, risk stratification at > 11 points
predicted a worse prognosis.
(See figure on previous page.)
Fig. 2 Cancer-specific survival (CSS) rates of the groups categorized by expression levels of a ARL4C, b ECT2, c SOD2, and d STEAP3 in a cohort
of 97 patients with RCC. The high-expression groups were associated with significantly shorter CSS than the low-expression groups for each
individual biomarker (log rank test, a p < 0.001, chi-square value = 28.11, b p = 0.023, chi-square value = 5.18, c p = 0.005, chi-square value =
8.02, d p < 0.001, chi-square value = 24.35). e The patients were divided into high- and low-risk scored groups under our model of risk
stratification by setting the cut-off value to 4 points; high- (> 4) risk scored groups had significantly shorter survival than low- (≤ 4) risk scored
groups (e log-rank test, p < 0.001, chi-square value =22.34). The latter had better prognosis without disease-specific death. f The cut-off value was
shifted to 11 points; the high- (> 11) risk scored group now encompasses patients with a worse prognoses and likely demise within 5 years (f
log-rank test, p < 0.001, chi-square value = 34.24)
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Association of four gene products with cancer-specific
survivals in metastatic renal cell carcinomas and
prognostic performance of multiple biomarker models
We analyzed 36 cases of metastatic RCCs including 27
cases of metastasis at the initial diagnosis and 9 of dis-
tant occurrence after first surgery in order to evaluate
the prognostic capacity of our risk stratification model
and to compare its performance with that of each indi-
vidual biomarker. Shorter CSS from the time of diagno-
sis of metastasis was significantly associated with
stronger expression of ARL4C, SOD2, and STEAP3. The
2-year CSS from diagnosis of metastasis in high and low
ARL4C groups was 46.9% and 93.3%, respectively (log-
rank test p = 0.006, chi-square value = 7.53, Fig. 3a).
These values were 59.3% and 82.4% for ECT2 (log-rank
test p = 0.073, chi-square value = 3.22, Fig. 3b), 45.7%
and 84.8% for SOD2 (log-rank test p = 0.011, chi-square
value = 6.54; Fig. 3c), and 46.9% and 82.6% for STEAP3
(log-rank test p = 0.003, chi-square value = 8.95, Fig,
3d), respectively. According to multivariate Cox propor-
tional hazards models, the presence of metastasis at
diagnosis (HR = 6.26, 95% CI = 1.19-33.00, p = 0.031)
and high SOD2 expression (HR = 4.97, 95% CI = 1.12–
22.02, p =0.035) were significantly associated with
shorter CSS intervals in 36 metastatic RCC patients
(Table 3). Compared to SOD2, our model for risk strati-
fication performed well, especially for predicting early
deaths when the cut-off score was increased to > 17
points; i.e., positivity of ARL4C and additionally STEAP3
or > 2 other biomarkers. With this cut-off, the 2-year
CSS from diagnosis of metastasis in high- (> 17) and
low- (≤ 17) risk-scored groups was 26.7% and 94.4%, re-
spectively (log-rank test p < 0.001, chi-square value =
21.66, Fig. 3e). The high-scored group had progressively
lower survival rates of 26.7–13.3% (Fig. 3e) than those of
45.7–30.5% in the high-SOD2 group (Fig. 3c), at 2–5
years’ follow-up, respectively.
Risk stratification predicts prognosis of metastatic renal
cell carcinoma patients treated with molecular targeting
therapies
In addition, 25 cases treated with molecular targeted
therapies (MTT) were analyzed in order to evaluate
therapeutic efficacy. According to this additionally sub-
group analysis, the implementation of current MTT did
not improve CSS in cases displaying high SOD2 expres-
sion (log-rank test p = 0.009, chi-square value = 6.80,
Fig. 4a), or the highest (> 17 points) risk-scored patients
in our model of risk stratification (log-rank test p < 0.001,
chi-square value = 12.17; Fig. 4b). In contrast to our
model of risk stratification, high SOD2 expression was
better able to identify patients with the worst prognosis in
that all 9 patients with high SOD2 expression had died by
30 months from initiation of MTT.
Discussion
In this study, we identified two clinical meaningful find-
ings by developing a risk-stratified model based on the
expression profiles of four biomarkers and by validating
its prognostic significance in our cohort. First, our risk
model could predict the prognosis of patients with RCC
more accurately and identify cases requiring closer
follow-up and medical management. Second, the current
molecular targeting therapies (MTT) are insufficient to
improve survival of metastatic RCC patients in the high-
risk group of our model, especially in those with high
SOD2 expression.
Higher expression levels by IHC for each of the four
biomarkers in primary RCC tissue were significantly as-
sociated with poor prognosis in the overall cohort of 97
cases including all stages of RCC. Of these 4 biomarkers,
ARL4C is a transcriptional factor induced by cooperative
signaling of Wnt/β-catenin and EGF/Ras-MAPK signal-
ing activation, which promotes proliferation, migration,
and invasion of cancer cells [16]. In previous studies,
high ARL4C expression was associated with poor prog-
nosis in some carcinomas [16–18]. Another of the four
biomarkers, ECT2, is a guanine exchange factor for the
Rho family of GTPases that has been associated with the
regulation of cell cycle progression and cytokinesis. The
dysregulation of ECT2 leads to malignant transformation
and enhances metastatic ability through upregulating the
epithelial mesenchymal transition process [19]. The third
biomarker, SOD2, is a primary mitochondrial antioxidant
reducing reactive oxygen species (ROS), and which can
prevent cell death and promote epithelial to mesenchymal
transition and/or cancer cell migration [9, 20]. Finally,
STEAP3 is a member of the iron regulatory protein family
and is a ferrireductase which reduces ferric iron to ferrous
iron in endosomes. It has been reported that STEAP3
overexpression facilitates iron uptake, maintains iron stor-
age in cancer cells and supports cancer cell proliferation
under hypoferric conditions [21, 22].
ARL4C was shown to be the most prognostic single
biomarker among four markers studied in multivariate
analysis, but our risk-stratified model with modified cut-
off value for the risk score showed better accuracy than
ARL4C prediction alone. When the cut-off point was set
to 4, low- (≤ 4) scored patients, i.e., positive for SOD2,
ECT2, or nothing, showed better survival rates and none
was deceased 8 years after primary nephrectomy. In
cases without expression of any biomarkers or with only
expression of SOD2 or ECT2 alone, close follow-up may
not be necessary except in metastatic cases. Conversely,
by setting the cut-off point to 11, the high-(> 11) scored
group, i.e., positive for ARL4C and additionally another
biomarker, identified patients likely to be dead within 5
years. These results indicate that ARL4C may contrib-
utes to more aggressive behavior of the tumor including
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Fig. 3 Cancer-specific survival rates of the groups categorized by expression levels of a ARL4C, b ECT2, c SOD2, and d STEAP3 in a cohort of 36
patients with metastatic RCC. Shorter survival from the time of diagnosis of metastasis is seen in cases with higher expression levels of ARL4C
(log-rank test, a p = 0.006, chi-square value = 7.53), SOD2 (log-rank test, c p = 0.011, chi-square value = 6.54), and STEAP3 (log-rank test, d p =
0.003, chi-square value = 8.95). e The patients were divided into high- and low-risk scored groups under our model of risk stratification by setting
the cut-off value to 17 points; the high- (> 17) risk score predicted likely demise within 2 years more accurately than each individual biomarker
(log-rank test, e p < 0.001, chi-square value = 21.66)
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Table 3 Prognostic evaluation of clinicopathological parameters for cancer-specific survival in 36 cases of metastatic renal cell
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Fig. 4 Cancer-specific survival (CSS) curves for 25 metastatic RCC treated with molecular targeting therapy (MTT) under the evaluation of a high
or low SOD2 expression, and of b high- (> 17) or low- (≤ 17) risk scoring in our model of risk stratification. In this sub-cohort, CSS was defined as
the period from the point of initiation of MTT to the time of RCC-specific death. Shorter CSS was observed in the high SOD2 expression group (a
log-rank test, p = 0.009, chi-square value = 6.80) and highest-risk (> 17) scored groups (b log-rank test, p < 0.001, chi-square value = 12.17).
Compared to the highest-risk scored group, high SOD2 expression could accurately predict those patients likely to be dead within 30 months of
initiation of MTT
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a possibility of metastasis, as demonstrated that high ex-
pression of ARL4C in lung, liver, and colorectal cancers
was an independent indicator of relapse [23, 24]. The
other three biomarkers may promote the progression
of metastatic tumors. These findings can offer us use-
ful information on the selection of cases for optimal
medical management. Thus, follow-up of RCC cases
with abundant ARL4C and additionally another bio-
marker should be more closely controlled with more
frequently follow-up.
In 36 patients with metastatic RCC, high- (> 17) scored
patients in our risk model, meaning positivity of ARL4C
or STEAP3 and additionally more than two other bio-
markers, always had worse survival and death at 2 to 5
years after diagnosis of metastasis. In our model, among
25 patients who received MTT, both the high-(> 17)
scored group and the high SOD2 group had a very poor
prognosis after initiation of MTT. In addition, the latter
SOD2 group predicted imminent death more accurately.
These findings indicate that each of the four molecules co-
ordinately accelerated the progression of metastatic can-
cers through individually different pathways, but
interestingly the most important indicator determining
whether long-term survival can be achieved by the current
MTT was simply the SOD2 expression level. Therefore,
we believe that novel and innovative therapeutic strategies
are required to achieve better prognosis in patients with
metastatic RCCs showing high SOD2 expression. The one
of mechanisms of MTT including inhibitors of tyrosine
kinase and mTOR kinase is based on nutrition-starvation
via inhibition of angiogenesis and/or interfering the cellu-
lar signaling of the aberrant proliferation activity of tumor
cells [25, 26]. However, cancer cells expressing highly
SOD2 can survive in a nutritionally depleted environment
via preserving mitochondrial function and preventing
ROS accumulation [27]. This helps to maintain the dor-
mant character in RCC development [8, 9]. It has been
previously demonstrated that inhibitors targeting mito-
chondrial oxidative phosphorylation such as biguanides
induce death of RCC cells and may become therapeutic
options to overcome the disastrous consequences of
SOD2-abundance in RCC cells [9]. Furthermore, the anti-
tumor effect of biguanides like metformin in patients with
diabetes has been demonstrated in several carcinomas
[28–32]. In order to target tumor cell mitochondria, ap-
plying biguanides to replacement therapy or drug reposi-
tioning should be proposed for patients with SOD2-
abundant RCC for maintenance phase treatments after
primary surgery debulking numbers of RCC cells.
Important limitations exist in the present study begin-
ning with the sample being drawn from a population of
patients at a single, small institute. The sample size, het-
erogeneity of the analyzed patients and lack of external
validation cohort may prevent generalization of the
study results to patients at the other institutions. How-
ever, even under such small and heterogenic cohort, the
present analysis has indicated enough statistical differ-
ences, and so we cannot deny that these announced
novel biomarkers are meaningful in prognostic and
therapeutic prediction of RCC patients. Secondly, it has
not been verified yet whether our risk-stratified model
can predict the prognosis of the patients who received
the current ICI treatment. Our cohort has included a
number of patients who previously treated before appli-
cation of the current ICI therapy. Under the current
prosperity of ICI therapeutics, the opportunities receiv-
ing a first-line MTT are declining. However, MTT has
been still required as an alternative to ICI, in the pa-
tients who cannot receive or tolerate ICI or who are re-
fractory to ICI. Therefore, it has been still essential to
predict the prognosis of patients undergoing MTT.
What remains unresolved is whether the assessment is
reproducible by other investigators. However, immuno-
histochemical evaluation is widely available at almost all
hospitals and can allow molecular expression levels to
be evaluated by qualitative grading in tumor cells by
comparing the staining intensity of RCC tissues with ad-
jacent normal proximal tubules.
We propose a risk stratification model constructed by
four novel biomarkers (ARL4C, ECT2, STEAP3, SOD2)
that can be used to predict CSS in RCC patients. The
risk stratification accurately predicts CSS in both whole
RCC patients and metastatic RCC sub-group. Although
our risk model showed enough prognostic prediction,
more accurate predictions might be performed, if the
risk model had included BIRC5 and BUB1 which had
been well-established prognostic function for RCC pa-
tients [12, 13]. We hope further prospective studies with
more samples from different medical centers will be able
to validate our prognostic signature and confirm its clin-
ical utility.
Conclusions
This study demonstrated that a risk-stratified model
based on four survival-related biomarkers could contrib-
ute to the clinical implications of prognostic prediction
and generate useful information for considering follow-
up and therapeutic strategies for patients with primary
and metastatic RCC.
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